Physician profile
Rene Eng
NPI 1629020151
$3,984.21
in general payments reported to CMS, 2019-2025
14 companies · $483 in 2025
The $483 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $385 · 2021: $1,020 · 2022: $671 · 2023: $382 · 2024: $456 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,275.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $615.76 | 2019-2025 | Xifaxan |
| Abbvie INC. | $408.26 | 2020-2024 | |
| Madrigal Pharmaceuticals | $124.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $108.83 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $108.32 | 2019-2020 | |
| Braintree Laboratories, INC. | $104.75 | 2019-2022 | |
| Qol Medical, LLC | $83.68 | 2025 | Sucraid |
| Celgene Corporation | $66.52 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $24.62 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $23.97 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $14.28 | 2019 | |
| Intra-Sana Laboratories | $12.87 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.